CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma Progression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
我们在此报告4例因疾病进展而无法接受idecabtagene vicleucel（ide-cel）的患者，尽管他们按规格完成了白细胞分离术。患者的中位年龄为70岁（范围68-77岁）。2例患者在诊断时为非分泌型亚型。既往治疗线的中位数为4.5（范围4-6），3例患者为五重难治性。所有患者对最近的治疗均难治。从白细胞分离术到ide-cel取消的中位时间为44.5天（范围：24-71天）。我们的发现表明，非分泌型亚型和五重难治性可能增加治疗中止的风险。早期应用ide-cel和改善桥接治疗是必要的，以提高白细胞分离术后的治疗完成率。
We herein report four patients who were unable to receive idecabtagene vicleucel (ide-cel) due to disease progression, despite undergoing leukapheresis within specification. The median age of the patients was 70 (range, 68-77) years old. Two patients had nonsecretory subtypes at the diagnosis. The median number of prior therapy lines was 4. 5 (range, 4-6), and 3 patients were penta-refractory. All patients were refractory to the latest treatment. The median time from apheresis to ide-cel cancellation was 44. 5 (range: 24-71) days.
Our findings suggest that the nonsecretory subtype and penta-refractoriness may increase the risk of treatment discontinuation. Early ide-cel application and improved bridging therapy are warranted to enhance treatment completion after leukapheresis.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
